Compare Adaptive Biotechnologies Corp (ADPT) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Las Vegas Sands Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Las Vegas Sands Corp. trades at $46.44 (market cap $30.52B). The key difference: Las Vegas Sands Corp. is far larger — about 9.2× Adaptive Biotechnologies Corp's market cap, and Las Vegas Sands Corp. pays a 2.39% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LVS | |
|---|---|---|
Market Cap | $3.33B | $30.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $69.49 |
52-Week Low | $10.24 | $46.06 |
Enterprise Value | $3.19B | $42.92B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LVS trades at $46.06, down 1.98% on the day, amid a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations, and maintains robust profitability with a net income margin of 13.41%. Recent news highlights ESG achievements and Macao's economic diversification efforts. Cash flow trends show positive net cash flow in 2025 after previous years of outflows.
The outlook for LVS is supported by solid fundamentals and analyst optimism, with a consensus price target of $66.38 implying significant upside. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and exposure to Macao's regulatory environment. Institutional sentiment remains positive, with no sell ratings among 49 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
